Effectiveness of oral diclofenac in the acute treatment of common migraine attacks: a double-blind study versus placebo.

Abstract

In a multicentre double-blind cross-over trial, oral diclofenac at a dose of 50 mg to 100 mg was compared to placebo in the acute treatment of migraine attacks. A hundred and seven patients suffering from migraine without aura were included, and 91 were analysed for efficacy; they had to treat four successive attacks--two with diclofenac and two with placebo. Diclofenac was significantly more effective than placebo (p less than 0.05) on the main judgement parameter, which was the number of attacks aborted within 2 h of drug intake, as well as on the following secondary parameters: the necessity for an escape medication and the evaluation of global efficacy. Diclofenac was well tolerated. This trial demonstrates the efficacy of diclofenac in the acute treatment of migraine attacks. It confirms the good clinical relevance of the main judgement parameter chosen, which is the one recommended by the International Headache Society, but appears to be a severe one in terms of successes.

• Authors: H Massiou, D Serrurier, O Lasserre, M G Bousser
• Journal: Cephalalgia : an international journal of headache (Cephalalgia) Vol. 11 Issue 2 Pg. 59-63 (May 1991) ISSN: 0333-1024 [Print] England
• PMID: 1860132 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Diclofenac

Topics

• Administration, Oral
• Adult
• Diclofenac (administration & dosage, adverse effects, therapeutic use)
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Migraine Disorders (drug therapy)
• Safety